Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: A 7-year follow-up of a randomized double-blind trial

European Archives of Psychiatry and Clinical Neuroscience

Volumn 255, Issue 2, 2005, Pages 121-128

  Rufer, Michael ^a,b   Hand, Iver ^a   Alsleben, Heike ^a   Braatz, Anne ^a   Ortmann, Jürgen ^a   Katenkamp, Birgit ^a   Fricke, Susanne ^a   Peter, Helmut ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cognitive behavioral therapy; Fluvoxamine; Follow up; Obsessive compulsive disorder; Outcome

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; FLUVOXAMINE; PLACEBO;

ADULT; ANAMNESIS; ARTICLE; BEHAVIOR THERAPY; CHRONIC PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LONG TERM CARE; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; OBSESSIVE COMPULSIVE DISORDER; PREDICTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; AGE OF ONSET; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; EMPLOYMENT; FEMALE; FLUVOXAMINE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MARRIAGE; OBSESSIVE-COMPULSIVE DISORDER; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 17744367459     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-004-0544-8     Document Type: Article

References (44)

1. Alonso P, Menchon JM, Pifarre J, Mataix Cols D, Torres L, Salgado P, Vallejo J (2001) Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. J Clin Psychiatry 62:535-540
2. Ballenger JC (1999) Current treatments of the anxiety disorders in adults. Biol Psychiatry 46:1579-1594
3. Basoglu M, Lax T, Kasvikis Y, Marks IM (1988) Predictors of improvement in obsessive-compulsive disorder. J Anxiety Disord 2:299-317
4. Bobes J, González MP, Bascarán MT, Arango C, Sáiz PA, Bousono M (2001) Quality of life and disability in patients with obsessive-compulsive disorder. European Psychiatry 16:239-245
5. Bouvard MA, Milliery M, Cottraux J (2004) Management of obsessive compulsive disorder. Psychother Psychosom 73:149-157
6. Büttner-Westphal H, Hand I (1991) Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), deutsche Übersetzung und Bearbeitung. Verhaltenstherapie 1:226-233
7. CIPS (1990) Internationale Skalen für Psychiatrie. Beltz, Weinheim
8. Cottraux J, Mollard E, Bouvard M, Marks I (1992) Exposure therapy, Fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year follow-up. Psychiatry Res 49:63-75
9. Cottraux J, Mollard E, Bouvard M, Marks I, Sluys M, Nury AM, Douge R, Cialdella P (1990) A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol 5:17-30
10. Doyle AC, Pollack MH (2003) Establishment of Remission Criteria for Anxiety Disorders. J Clin Psychiatry 64:40-45
11. Foa EB (1979) Failure in treating obsessive-compulsives. Behavior Research and Therapy 17:169-176
12. Foa EB, Grayson JB, Steketee G, Doppelt HG, Turner RM, Latimer PR (1983) Success and failure in the behavioral treatment of obsessive-compulsives. J Consult Clin Psychol 51:287-297
13. Fricke S, Moritz B, Andresen B, Hand I, Jacobsen M, Kloss M, Rufer M (2003) Einfluss von Persönlichkeitsstörungen auf den Erfolg einer multimodalen Verhaltenstherapie bei Zwangserkrankungen - Teil II: Ergebnisse einer empirischen Studie. Verhaltenstherapie 13:172-182
14. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS (1989) The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 46:1012-1016
15. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS (1989) The Yale-Brown Obsessive-Compulsive Scale. I.Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011
16. Grabe HJ, Meyer C, Hapke U, Rumpf HJ, Freyberger HJ, Dilling H, John U (2001) Lifetime-comorbidity of obsessive-compulsive disorder and subclinical obsessive-compulsive disorder in northern Germany. Eur Arch Psychiatry Clin Neurosci 251:130-135
17. Grabe HJ, Meyer C, Hapke U, Rumpf HJ, Freyberger HJ, Dilling H, John U (2000) Prevalence, quality of life and psychosocial functioning in obsessive-compulsive disorder and subclinical obsessive-compulsive disorder in northern Germany. Eur Arch Psychiatry Clin Neurosci 250:262-268
18. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
19. Hand I (2000) Group exposure in vivo for agoraphobics (1974): a multifaceted pilot study and its impact on subsequent agoraphobia research. Behav Cogn Psychother 28:335-351
20. Hand I (1998) Out-patient, multimodal behaviour therapy for obsessive-compulsive disorder. Br J Psychiatry 173:45-52
21. Hand I, Peter H, Rufer M (2001) Kombinationsbehandlung mit Verhaltenstherapie und Pharmakotherapie bei Zwangsstörungen. Verhaltenstherapie 11:206-216
22. Hohagen F, Winkelmann G, Rasche-Räuchle H, Hand I, Münchau N, Hiss H, Geiger-Kabisch C, Käppler P, Schramm P, Rey E, Aldenhoff J, Berger M (1998) Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. Br J Psychiatry 173:71-78
23. Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH, Janavs J, Dunbar GC (1997) The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 12:224-231
24. Leonard HL, Swedo SE, Lenane MC, Rettew DC, Cheslow DL, Hamburger SD, Rapoport JL (1991) A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 48:922-927
25. Marks IM (1997) Behaviour therapy for obsessive-compulsive disorder: a decade of progress. Can J Psychiatry 42:1021-1027
26. Marks IM, Stern RS, Mawson D, Cobb J, McDonald R (1980) Clomipramine and exposure for obsessive-compulsive rituals. Br J Psychiatry 136:1-25
27. Masellis M, Rector NA, Richter MA (2003) Quality of life in OCD: Differential impact of obsessions, compulsions, and depression comorbidity. Can J Psychiatry 48:72-77
28. Mawson D, Marks IM, Ramm L (1982) Clomipramine and exposure for chronic obsessive-compulsive rituals: Two year follow-up and further findings. Br J Psychiatry 140:11-18
29. Moritz S, Fricke S, Jacobsen D, Kloss M, Wein C, Rufer M, Katenkamp B, Farhumand R, Hand I (2004) Positive schizotypical symptoms predict treatment outcome in obsessive-compulsive disorder. Behav Res Ther 42:217-227
30. Moritz S, Meier B, Hand I, Schick M, Jahn H (2004) Dimensional structure of the Hamilton Depression Rating Scale in patients with obsessive-compulsive disorder. Psychiatry Res 125:171-180
31. Nierenberg AA, DeCecco LM (2001) Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: A focus on treatment-resistant depression. J Clin Psychiatry 62:16
32. O'Sullivan G, Noshirvani H, Marks IM, WM, Lelliott P (1991) Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder. J Clin Psychiatry 52:150-155
33. Pato MT, Zohar-Kadouch R, Zohar J, Murphy DL (1988) Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 145:1521-1525
34. Perugi G, Akiskal HS, Pfanner C, Presta S, Milanfranchi A, Lensi P, Ravagli S, Maremmani I, Cassano GB (1998) Episodic course in obsessive-compulsive disorder. Eur Arch Psychiatry Clin Neurosci 248:240-244
35. Rufer M, Hand I, Braatz A, Alsleben H, Fricke S, Peter H (2004) A prospective study of alexithymia in obsessive-compulsive patients treated with multimodal cognitive-behavioral therapy. Psychother Psychosom 73:101-106
36. Ruhmland M, Margraf J (2001) Effektivität psychologischer Therapien von spezifischer Phobie und Zwangsstörung: Meta-Analysen auf Störungsebene. Verhaltenstherapie 11:14-26
37. Sheehan DV, Lecrubier Y, Sheehan KH, Janavs J, Weiller E, Keskiner A, Schinka J, Knapp E, Sheehan MF, Dunbar GC (1997) The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 12:232-241
38. Skoog G, Skoog I (1999) A 40-year follow-up of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 56:121-127
39. Spitzer RL, Williams JB, Gibbsons M (1984) The Structured Clinical Interview for DSM-III-R, New York: New York State Psychiatric Institute, Biometric Research Department
40. Steketee G (1993) Social support and treatment outcome of obsessive compulsive disorder at 9-month follow-up. Behav Psychother 21:81-95
41. Steketee G, Chambless DL, Tran GQ (2001) Effects of axis I and II comorbidity on behavior therapy outcome for obsessive-compulsive disorder and agoraphobia. Compr Psychiatry 42:76-86
42. Steketee G, Eisen J, Dyck I, Warshaw M, Rasmussen S (1999) Predictors of course in obsessive-compulsive disorder. Psychiatry Res 89:229-238
43. Steketee G, Shapiro LJ (1995) Predicting behavioral treatment outcome for agoraphobia and obsessive compulsive disorder. Clin Psychol Rev 15:317-346
44. Wittchen HU, Zaudig M, Schramm E, Spengler P (1988) Strukturiertes klinisches Interview für DSM-III-R (SKID), Weinheim: Beltz